Low-dose Colchicine for Thromboprophylaxis After Transcatheter Aortic Valve Replacement

This prospective, randomized, open-label study aims to evaluate the efficacy and safety of low-dose colchicine (0.5 mg daily) in reducing transcatheter heart valve (THV) thrombosis in patients after TAVR. Participants will be randomly assigned to either receive colchicine plus standard care or standard care alone for 12 months. The primary goal is to compare the rate of valve thrombosis between the two groups using 4D-CT imaging at one year. Additionally, the study will evaluate the treatment's impact on clinical outcomes and its overall safety profile.

NCT Number	NCT07411768
Lead Sponsor	China National Center for Cardiovascular Diseases Collaborators: Chinese Academy of Medical Sciences
Conditions	Transcatheter Aortic Valve Replacement, Transcatheter Heart Valve Thrombosis, Anti-inflammatory Therapy
Enrollment	116 participants
Start Date	2026-03
Primary Completion	2028-06 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2026-03-12